Page last updated: 2024-09-03

imatinib mesylate and Cancer of Skin

imatinib mesylate has been researched along with Cancer of Skin in 149 studies

Research

Studies (149)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.67)	18.2507
2000's	56 (37.58)	29.6817
2010's	74 (49.66)	24.3611
2020's	18 (12.08)	2.80

Authors

Authors	Studies
Berking, C; Erdmann, M; Heppt, MV; Kohl, C; Petzold, A; Steeb, T; Wessely, A	1
Gounder, MM; Mori, S; Navarrete-Dechent, C; Nehal, KS; Shah, K; Stambuk, HE	1
Barrios Barreto, R; De La Hoz Pabola, A; Del Valle, A; Mendoza Suarez, L; Silvera Redondo, C	1
Amagai, R; Asano, Y; Fujimura, T; Hashimoto, A; Kambayashi, Y; Kasahara, Y; Ohuchi, K	1
Griewank, K; Hadaschik, E; Jansen, P; Kretz, J; Livingstone, E; Lodde, G; Meier, F; Möller, I; Schadendorf, D; Schlein, C; Song, M; Stadtler, N; Sucker, A; Zaremba, A; Zimmer, L	1
Berman, RS; Lee, AY; Vitiello, GA	1
Adams, A; Batchu, S; Cerniglia, KS; Goodwin, BJ; Henry, OS; Hong, YK; Platoff, R; Sandilos, G	1
Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M	1
Alacacıoğlu, A; Bütün, O; Demirdöver, C; Güç, H; Güç, ZG	1
Levell, NJ; Lim, SX; Ramaiya, A; Venables, ZC	1
Fang, L; Jia, W; Liu, C; Quan, P; Song, Y; Sun, H; Wang, J	1
Ahn, C; Allen, A; Sangüeza, OP	1
Brown, R; Caliskan, PM; Cove, L; David, MP; Dicker, G; Funderburg, A; Gardner, JM; Hoffman, L; Horne, T; Selig, JP	1
Abdou, Y; Ernstoff, MS; Hamad, L; Kapoor, A	1
Aickara, DJ; McBride, J; Morrison, B; Romanelli, P	1
Boukhar, SA; McGee, MW; Monga, V; Phadke, SD; Weigel, R	1
Botella-Estrada, R; de Unamuno-Bustos, B; Navarro-Mira, MÁ; Torres-Navarro, I	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Bielack, SS; Feuchtgruber, S; Fuchs, J; Hettmer, S; Klingebiel, T; Koscielniak, E; Krewer, J; Mentzel, T; Münter, M; Niggli, F; Rolle, U; Scheer, M; Seitz, G; Sparber-Sauer, M; Vokuhl, C; von Kalle, T	1
Han, X; Li, C	1
Charvát, M; Grossmann, P; Hrudka, J; Kinkor, Z	1
Biatta, CM; Centurioni, MG; Comandini, D; Cozzani, E; Franchelli, S; Merlo, G; Parodi, A; Trave, I; Vellone, VG; Zena, M	1
Shah, A; Sharma, S; Tassavor, M; Torbeck, R	1
Dębiec-Rychter, M; Jagielska, B; Klimczak, A; Pieńkowska-Grela, B; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I	1
Espinet, B; Gallardo, F; García-Martínez, P; Hernandez-Muñoz, M; Llistosella, E; Pujol, RM; Rodríguez-Rivera, M; Sitjas, D	1
Bambara, HA; Lamien/Sanou, A; Ouédraogo Nde, NA; Ouédraogo, MS; Ouédraogo, NA; Tapsoba, GP; Thouraya Chtioui, A; Tiemtoré-Kambou, BM; Traoré, F; Zongo, N	1
Dummer, R; French, LE; Goldinger, SM; Kränzlin-Stieger, P; Murer, C	1
Cho, J; Jang, KT; Kim, JH; Kim, K; Kim, NKD; Kim, ST; Kim, SY; Kim, YJ; Lee, J; Park, W; Sim, MH	1
Appay, R; Aubert, S; Bouvier, C; Delteil, C; Macagno, N; Magis, Q; Malissen, N; Richard, MA	1
Adabra, K; Amavi, AK; Dosseh, ED; Dossouvi, T; Padaro, E	1
Ben-Ami, E; Castells, MC; Connell, NT; Rutherford, AE; Thornton, KA	1
Alsina, M; Llombart, B; Morgado-Carrasco, D; Requena, C; Sanmartín, O; Serra, C; Través, V	1
Barker, CA; Dickson, MA; Mori, S; Navarrete-Dechent, C; Nehal, KS	1
Bassett, RL; Carapeto, FCL; Eterovic, AK; Grimm, EA; Haydu, LE; Hong, DS; Lazar, AJ; Ma, J; Macedo, MP; McKean, M; Oba, J; Patel, KP; Roth, KG; Siroy, AE; Vo, P; Wang, WL; Woodman, SE	1
Amadour, L; Arifi, S; Benbrahim, Z; Elmernissi, F; Elmrabet, F; Harmouch, T; Mellas, N; Ouahbi, H; Oufkigh, AA; Tahiri, L	1
Haas, RL; Kerst, JM; Klomp, HM; van Boven, HH; van Coevorden, F; van der Hage, JA; van Huizum, MA; Wicherts, DA	1
Colegio, OR; Liu, LS	2
Chaudhary, SC; Jain, N; Kumar, V; Mishra, S	1
Messingham, KN; Srikantha, R; Swick, BL	1
Beadling, C; Collichio, FA; Corless, CL; Demetri, GD; Ernstoff, MS; Fisher, DE; Flaherty, KT; Fletcher, JA; Friedlander, P; Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Heinrich, MC; Hodi, FS; Kim, KB; Lawrence, D; Luke, JJ; Marino-Enriquez, A; O'Day, SJ; Van den Abbeele, AD; Weber, JS; Yap, JT; Zhu, M; Zukotynski, KA	1
Akram, J; Lock-Andersen, J; Wooler, G	1
Carvajal, RD	1
Baumgartner, M; Becker, JC; Breier, F; Feldmann, R; Loader, DE; Schrama, D; Steiner, A	1
Adenis, A; Amela, EY; Blay, JY; Bui-Nguyen, B; Cassier, PA; Chauzit, E; Clisant, S; Fournier, C; Italiano, A; Molimard, M; Penel, N; Ray-Coquard, I; Tresch-Bruneel, E	1
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Butori, C; Dumaz, N; Giacchero, D; Hofman, P; Hofman, V; Lacour, JP; Segalen, C	1
Bauer, R; Geisler, K; Jacobs, B; Kroeger, I; Mackensen, A; Meinhardt, K; Reischer, A; Ryffel, B; Ullrich, E	1
Al-Refaie, W; Atkins, MB; Parks, K; Rapisuwon, S	1
Aldabagh, B; Joo, J; Yu, SS	1
Agopian, J; Bertucci, F; Chauvot de Beauchêne, I; De Sepulveda, P; Dubreuil, P; Fouet, B; Fournier, B; Mescam-Mancini, L; Panel, N; Tchertanov, L; Tisserand, JC; Vita, M	1
Blank, C; Cornelissen-Steijger, PD; Geukes Foppen, MH; Goding, CR; Graeber, TG; Haanen, J; Hugo, W; Kemper, K; Kong, X; Krijgsman, O; Lo, RS; McDermott, U; Müller, J; Peeper, DS; Possik, PA; Ribas, A; Robert, L; Song, C; Tsoi, J	1
Fujii, M; Honma, M; Iizuka, H; Ishida-Yamamoto, A; Iwasaki, T; Kishiyama, K; Takahashi, H; Takahashi, I	1
Kallini, JR; Khachemoune, A	1
Amin, A; Aslam, HM; Bashir, S; Hashmi, AS; Malik, B; Mumtaz, S; Tariq, M	1
Chen, J; Chen, Y; Luo, Z; Shi, Y; Wang, C; Zhang, R; Zheng, B	1
Astolfi, A; Casali, PG; Castelli, C; Conca, E; Dagrada, GP; Dei Tos, AP; Fiore, M; Gronchi, A; Grosso, F; Indio, V; Maestro, R; Negri, T; Palassini, E; Pantaleo, MA; Pilotti, S; Stacchiotti, S; Tazzari, M; Urbini, M; Vincenzi, B	1
Green, G; Moslehi, H; Ortiz-Urda, S; Panzer-Grümayer, R; Posch, C; Rappersberger, K; Sanlorenzo, M; Vujic, I	1
Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G	1
Griewank, KG	1
Fukushima, T; Gomi, D; Kobayashi, T; Koizumi, T; Sakamoto, A; Sano, K; Sasaki, S; Sekiguchi, N; Tatai, T	1
Arienti, F; Astolfi, A; Camisaschi, C; Casali, PG; Castelli, C; Dagrada, GP; De Cecco, L; Fiore, M; Gronchi, A; Indio, V; Lombardo, C; Negri, T; Pantaleo, MA; Pilotti, S; Rini, F; Rivoltini, L; Stacchiotti, S; Tazzari, M; Vergani, B; Villa, A	1
Borthakur, G; Cortes, JE; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Koller, PB; Nogueras-Gonzalez, GM; O'Brien, SM; Ravandi, F; Verstovsek, S; Wierda, WG	1
Inayat, F; Saif, MW	1
Becker, JC; Ugurel, S	1
Linden, KG; Ortiz, AE; Wu, JJ	1
Goldenberg, G; Golitz, LE; McCarter, M; McClain, D; Thomison, J	1
Bar-Eli, M; Bedikian, AY; Billings, LA; Camacho, LH; Charnsangavej, C; Cormier, JN; Davis, DW; Diwan, AH; Eton, O; Frazier, ML; Gershenwald, JE; Johnson, MM; Kim, KB; Lee, JE; Mansfield, PF; McConkey, DJ; Murgo, AJ; Ng, CS; Papadopoulos, NE; Prieto, VG; Ross, MI	1
Aklan, T; Hoeffken, K; Lemm, D; Mentzel, T; Muegge, LO; Schultze-Mosgau, S; Thorwarth, M	1
Höffken, K; Lemm, D; Mentzel, T; Mügge, LO	1
Duffaud, F; Le Cesne, A	1
Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Taniguchi, H	1
Chen, EH; Han, A; Niedt, G; Ratner, D; Sherman, W	1
Almenar, S; Guillén, C; Llombart, B; Llombart-Bosch, A; López-Guerrero, JA; Monteagudo, C; Poveda, A; Requena, C; Sanmartín, O; Serra, C; Vistós, JL	1
Adamson, DC; Cummings, TJ; Grossi, PM; Mattox, AK; Mehta, AI	1
Bernengo, MG; Fava, P; Savoia, P; Stroppiana, E	1
Bartal, A; Bocs, K; Hitre, E; Langmár, Z; Liszkay, G; Mátrai, Z; Orosz, Z; Plotár, V; Rényi Vámos, F; Sávolt, A; Székely, J; Tóth, L	1
Becker, JC; Houben, R; Pajouh, P; Terheyden, P; Thorns, C; Zillikens, D	1
Gutzmer, R; Kapp, A; Küttler, U; Satzger, I; Schenck, F; Völker, B	1
Balzer-Haas, NS; DeConti, RC; Flaherty, LE; Heinrich, MC; Merl, SA; Moon, J; Samlowski, WE; Sondak, VK; Thompson, JA; Tuthill, RJ; Witter, MT	1
Bzyl, J; Fusenig, NE; Heusel, J; Kiessling, F; Lederle, W; Linde, N; Mueller, MM; Skobe, M; Woenne, EC; Zwick, S	1
Baker, LH; Verweij, J	1
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A	1
Aubin, F; Bodokh, I; Boulinguez, S; Calvo, F; D'Incan, M; Dalle, S; de Kerviler, E; Janin, A; Kérob, D; Lebbe, C; Madelaine-Chambrin, I; Mathieu-Boue, A; Maubec, E; Pedeutour, F; Porcher, R; Servant, JM; Vérola, O	1
Ando, N; Harada, K; Kawamura, T; Shibagaki, N; Shimada, S; Yamaguchi, M	1
Dębiec-Rychter, M; Michej, W; Nowecki, Z; Ptaszynski, K; Ruka, W; Rutkowski, P; Symonides, M	1
Al-Sarraf, R; Johnson, CS; Malone, EK; Rassnick, KM; Ruslander, DM; Russell, DS; Trump, DL; Wakshlag, JJ	1
Johnson-Jahangir, H; Ratner, D; Sherman, W	1
Balagula, Y; Busam, KJ; Carvajal, RD; Myskowski, PL; Wolchok, JD	1
Martin, L	1
Bauer, J; Eigentler, TK; Garbe, C; Held, L; Held, M; Meier, F; Röcken, M	1
O'Bryan, KW; Ratner, D	1
Antonescu, CR; Bastian, BC; Bouvier, N; Busam, KJ; Cane, L; Carvajal, RD; Chapman, PB; Chmielowski, B; Fusco, A; Lutzky, J; Panageas, KS; Pavlick, AC; Roman, RA; Schwartz, GK; Takebe, N; Teitcher, J; Vemula, S; Wolchok, JD	1
Chi, Z; Corless, CL; Cui, C; Du, N; Flaherty, KT; Guo, J; Han, M; Kong, Y; Li, H; Li, J; Li, L; Li, S; Lin, X; Mao, L; Qin, S; Sheng, X; Si, L; Wang, B; Xu, X; Zhang, X; Zhu, Y	1
Li, QW; Lu, JY; Sun, JZ; Wang, RL; Xiao, WH; Zhu, JH	1
Bosenberg, M; Curley, DP; Damsky, WE; Dankort, D; Gould Rothberg, BE; McMahon, M; Platt, JT; Rimm, DL; Rosenbaum, LE; Santhanakrishnan, M; Taketo, MM	1
Tawbi, HA; Tran, A	1
Malhotra, B; Schuetze, SM	1
Botella-Estrada, R; Nagore, E; Rubio, L; Soriano, V	1
Dummer, R; Eggmann, N; Goldinger, SM; Rinderknecht, J; Rozati, S	1
Clarke, LE	1
Lee, VK; Ong, CW; Pang, B; Tay, CM	1
Llombart, B; López Guerrero, JA; Monteagudo, C; Sanmartín, O; Serra-Guillén, C	1
Blay, JY; Ray-Coquard, I	1
Sawyers, CL	1
Bruckner, JD; Conrad, EU; Eary, JF; Mirza, S; Norwood, TH; Rubin, BP; Schuetze, SM	1
Antonescu, CR; Awan, RA; Dixon, RH; Jhanwar, S; Maki, RG	1
Kuenen, BC; Pinedo, HM	1
Baars, A; Pinedo, HM	1
Abruzzese, E; Amadori, S; Anemona, L; Campione, E; Cantonetti, M; Del Principe, MI; Masi, M; Morino, L; Orlandi, A; Orlandi, G; Tendas, A	1
Bekkenk, MW; Jansen, PM; Meijer, CJ; Middeldorp, JM; Stevens, SJ; Vermeer, MH; Willemze, R	1
Bar-Eli, M; Eton, O; Heimberger, A; McGary, EC; Mills, L; Onn, A; Shtivelband, M; Thomas, GW	1
McArthur, G	2
All-Ericsson, C; Brodin, B; Girnita, L; Larsson, O; Müller-Brunotte, A; Ostman, A; Seregard, S	1
Hara, K; Matsumoto, Y; Mizutani, K; Saeki, H; Tamada, Y; Tamaki, K; Tsuzuki, T	1
Bubley, GJ; Chatis, P; Crosby, K; Dezube, BJ; Egorin, MJ; Koon, HB; Masiello, D; Miller, TE; Pantanowitz, L; Proper, J; Smith, B; Tahan, SR; Weeden, W	1
Grossman, D	1
Andreu, EJ; Inoges, S; Lloret, P; Redondo, P	1
Alimena, G; Breccia, M; Carmosino, I; Latagliata, R; Morano, SG; Russo, E	1
Corless, CL; Debiec-Rychter, M; Demetri, GD; Dimitrijevic, S; Fletcher, JA; Heinrich, MC; McArthur, GA; Nikolova, Z; van Oosterom, A	1
Fletcher, JA; Labropoulos, SV; Oliveira, AM; Papadopoulos, S; Razis, ED	1
Bakhanashvili, M; Beery, E; Birenbaum, M; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Reshef, H; Sandbank, J; Uziel, O; Yerushalmi, R	1
Scheinfeld, N; Schienfeld, N	1
Bigby, SM; Lambie, NK; Oei, P; Symmans, PJ	1
Devere, TS; Heinrich, MC; Lee, KK; Mehrany, K; Swanson, NA; Weenig, RH; White, CR	1
Akioka, T; Endo, Y; Hanafusa, T; Hara, S; Hirata, Y; Kobayashi, K; Oka, S; Tsuji, M; Yamano, T; Yokote, T	1
O'Brien, SG; Reilly, JT; Simpson, E	1
McArthur, GA	2
Choi, WS; Chung, HS; Kim, SD; Kim, SH; Lim, DJ; Park, JY	1
Bastian, BC; Busam, K; Curtin, JA; Pinkel, D	1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Hungerford, JL; Hurren, J; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Whitehouse, PA	1
Bernengo, MG; Ortoncelli, M; Quaglino, P; Savoia, P	1
Hioki, K; Kawabata, M; Kobie, K; Maruo, K; Matsuda, H; Mori, T; Tanaka, A	1
Awada, A; De Saint Aubain, N; Flamen, P; Gil, T; Kasper, B; Lossignol, D	1
Ikeda, E; Sakurai, N; Sasou, S; Shibuma, H; Yamauchi, J	1
Bianchini, L; Maire, G; Pedeutour, F	1
Ugurel, S	1
Correa-Rotter, R; Volkow, P; Zinser, JW	1
Guillén, C; Llombart, B; López-Guerrero, JA; Requena, C; Sanmartín, O; Serra, C	1
Petersen, JE; Wright, TI	1
Nishida, T	1
Fernandez-Flores, A	1
Fitzpatrick, JE; Ravdel, L; Robinson, WA; Swick, BL	1
Alberti, L; Arifi, S; Blay, JY; Cassier, P; Decouvelaere, AV; Dufresne, A; El Sayadi, H; Fayette, J; Méeus, P; Ranchère, D; Ray-Coquard, I; Tabone-Eglinger, S	1
Kawakami, Y; Kimura, H; Nakamura, K; Nishibu, A; Yamamoto, T; Yanagihori, H	1
Bousquet, G; Calvo, F; de Kerviler, E; Janin, A; Kerob, D; Lebbe, C; Leboeuf, C; Madelaine-Chambrin, I; Pedeutour, F; Pruvost, C; Sarandi, F; Servant, JM; Verola, O	1
Buchdunger, E; Collins, VP; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T	1
Buchdunger, E; Dal Cin, P; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T	1

Reviews

34 review(s) available for imatinib mesylate and Cancer of Skin

Article	Year
c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Dasatinib; Exons; Humans; Imatinib Mesylate; Melanoma; Mucous Membrane; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin; Skin Neoplasms; Sunitinib; Sunlight	2021
Dermatofibrosarcoma Protuberans: What Is This? The Surgical clinics of North America, 2022, Volume: 102, Issue:4 Topics: Dermatofibrosarcoma; Humans; Imatinib Mesylate; Margins of Excision; Skin Neoplasms	2022
Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review. American journal of surgery, 2023, Volume: 225, Issue:2 Topics: Adolescent; Adult; Aged; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Skin Neoplasms; Tyrosine Kinase Inhibitors; Young Adult	2023
Dermatofibrosarcoma Protuberans. Dermatologic clinics, 2019, Volume: 37, Issue:4 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Humans; Imatinib Mesylate; Margins of Excision; Mohs Surgery; Oncogene Proteins, Fusion; Skin Neoplasms; Translocation, Genetic	2019
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans. Actas dermo-sifiliograficas, 2018, Volume: 109, Issue:10 Topics: Antineoplastic Agents; Combined Modality Therapy; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Grading; Neoplasm Staging; Oncogene Proteins, Fusion; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sarcoma; Skin Neoplasms	2018
Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review. JAMA dermatology, 2019, 03-01, Volume: 155, Issue:3 Topics: Adult; Aged; Dermatofibrosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Skin Neoplasms; Survival Analysis; Treatment Outcome; Young Adult	2019
[Outcome of locally advanced Darier and Ferrand dermatofibrosarcoma: about a case and literature review]. The Pan African medical journal, 2019, Volume: 32 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Skin Neoplasms; Treatment Outcome; Young Adult	2019
Molecularly targeted therapies for melanoma. International journal of dermatology, 2013, Volume: 52, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunotherapy; Indoles; Ipilimumab; Melanoma; Mesylates; Molecular Targeted Therapy; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sulfonamides; Vemurafenib	2013
Molecularly targeted therapies for nonmelanoma skin cancers. International journal of dermatology, 2013, Volume: 52, Issue:6 Topics: Anilides; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyridines; Pyrimidines; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms	2013
Merkel cell carcinoma: current status of targeted and future potential for immunotherapies. Seminars in cutaneous medicine and surgery, 2014, Volume: 33, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers; Carcinoma, Merkel Cell; CD56 Antigen; Electrochemotherapy; Hepatitis A Virus Cellular Receptor 2; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Indazoles; Inhibitor of Apoptosis Proteins; Interferons; Interleukin-12; Interleukin-2; Ipilimumab; Lymphatic Metastasis; Membrane Proteins; Merkel cell polyomavirus; Oligonucleotides, Antisense; Piperazines; Polyomavirus Infections; Prognosis; Programmed Cell Death 1 Receptor; Pyrimidines; Receptors, Somatomedin; Skin Neoplasms; Somatostatin; Sulfonamides; Survivin; Thionucleotides; TOR Serine-Threonine Kinases	2014
Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:12 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Young Adult	2014
Biomarkers in melanoma. Scandinavian journal of clinical and laboratory investigation. Supplementum, 2016, Volume: 245 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; CTLA-4 Antigen; Early Diagnosis; Humans; Imatinib Mesylate; Melanoma; Melanoma, Cutaneous Malignant; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Prognosis; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Skin Neoplasms	2016
Current treatment options in dermatofibrosarcoma protuberans. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cell Division; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Microsurgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Skin Neoplasms	2009
Imatinib in the treatment of solid tumours. Targeted oncology, 2009, Volume: 4, Issue:1 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Clinical Trials as Topic; Dermatofibrosarcoma; Fibromatosis, Aggressive; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms; Treatment Outcome	2009
Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology (Basel, Switzerland), 2010, Volume: 220, Issue:1 Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzamides; Female; Humans; Imatinib Mesylate; Melanoma; Mucous Membrane; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2010
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cytotoxins; Dermatofibrosarcoma; Disease Progression; Gastrointestinal Stromal Tumors; Hemangioendothelioma; Hemangiosarcoma; Humans; Imatinib Mesylate; Leiomyosarcoma; Liposarcoma, Myxoid; Piperazines; Pyrimidines; Research Design; Sarcoma; Sarcoma, Synovial; Skin Neoplasms	2010
[What's new in dermatological treatments?]. Annales de dermatologie et de venereologie, 2010, Volume: 137 Suppl 4 Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab	2010
Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2011, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; DNA Mutational Analysis; Drugs, Investigational; Humans; Imatinib Mesylate; Melanoma; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin Neoplasms	2011
The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:1 Topics: Anilides; Antineoplastic Agents; Benzamides; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dermatofibrosarcoma; ErbB Receptors; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms, Squamous Cell; Piperazines; Pyridines; Pyrimidines; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck	2011
A potential role for nilotinib in KIT-mutated melanoma. Expert opinion on investigational drugs, 2012, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2012
Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results. Current opinion in oncology, 2012, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2012
Fibrous and fibrohistiocytic neoplasms: an update. Dermatologic clinics, 2012, Volume: 30, Issue:4 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; beta Catenin; Dermatofibrosarcoma; Fibromatosis, Abdominal; Histiocytoma, Malignant Fibrous; Humans; Imatinib Mesylate; Myxosarcoma; Neprilysin; Neurothekeoma; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms; Solitary Fibrous Tumors	2012
KIT gene mutation analysis in solid tumours: biology, clincial applications and trends in diagnostic reporting. Pathology, 2013, Volume: 45, Issue:2 Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Melanoma; Mutation; Piperazines; Precision Medicine; Proto-Oncogene Proteins c-kit; Pyrimidines; Research Report; Skin Neoplasms	2013
Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Seminars in diagnostic pathology, 2013, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Skin Neoplasms; Translocation, Genetic	2013
Molecularly targeted treatment for dermatofibrosarcoma protuberans. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Drug Delivery Systems; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2004
Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms; Tomography, Emission-Computed; Tomography, X-Ray Computed	2004
Imatinib mesylate for melanoma: will a new target be revealed? The Journal of investigative dermatology, 2004, Volume: 123, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Melanoma; Piperazines; Pyrimidines; Skin Neoplasms	2004
A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:2 Topics: Animals; Benzamides; Dermatofibrosarcoma; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Skin Neoplasms	2006
Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Current opinion in oncology, 2006, Volume: 18, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Middle Aged; Models, Genetic; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin Neoplasms; Treatment Outcome	2006
[Dermatofibrosarcoma protuberans]. Actas dermo-sifiliograficas, 2007, Volume: 98, Issue:2 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Combined Modality Therapy; Dermatofibrosarcoma; Drug Design; Humans; Imatinib Mesylate; Mohs Surgery; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Ring Chromosomes; Sarcoma; Skin Neoplasms; Translocation, Genetic	2007
Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dermatofibrosarcoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Humans; Imatinib Mesylate; Molecular Biology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiotherapy, Adjuvant; Skin Neoplasms	2007
Dermatofibrosarcoma protuberans: recent clinical progress. Annals of surgical oncology, 2007, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Clinical Trials as Topic; Combined Modality Therapy; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin; Skin Neoplasms; Translocation, Genetic	2007
[Imatinib and solid tumours]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasms; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2008

Trials

13 trial(s) available for imatinib mesylate and Cancer of Skin

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma. Journal of cutaneous pathology, 2013, Volume: 40, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Carcinoma, Merkel Cell; Codon; Exons; Female; Gastrointestinal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation, Missense; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Skin Neoplasms	2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chronic Disease; Female; Gene Amplification; GTP Phosphohydrolases; Humans; Imatinib Mesylate; Male; Melanoma; Membrane Proteins; Middle Aged; Mucous Membrane; Mutation; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight; Survival Rate	2013
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10 Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chordoma; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasms; Piperazines; Pyrimidines; Skin Neoplasms	2013
Phase II trial of imatinib mesylate in patients with metastatic melanoma. British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Disease Progression; DNA Primers; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Piperazines; Positron-Emission Tomography; Pyrimidines; Skin Neoplasms; Treatment Outcome	2008
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). American journal of clinical oncology, 2010, Volume: 33, Issue:5 Topics: Aged; Aged, 80 and over; Benzamides; Carcinoma, Merkel Cell; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Survival Analysis	2010
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-15, Volume: 16, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2010
Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and comparative oncology, 2010, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Calcitriol; Calcium Channel Agonists; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Female; Imatinib Mesylate; Indoles; Lomustine; Male; Mastocytoma; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Calcitriol; Skin Neoplasms; Treatment Outcome; Vinblastine	2010
KIT as a therapeutic target in metastatic melanoma. JAMA, 2011, Jun-08, Volume: 305, Issue:22 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Survival Analysis; Treatment Outcome	2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; China; Disease-Free Survival; Exons; Female; Gene Amplification; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Risk Factors; Skin Neoplasms; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; United States	2011
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-10, Volume: 23, Issue:5 Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A	2005
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Disease-Free Survival; Female; Gene Rearrangement; Genes, sis; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2005
The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Research in veterinary science, 2007, Volume: 82, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Dog Diseases; Dogs; Imatinib Mesylate; Mast-Cell Sarcoma; Mice; Mice, SCID; Piperazines; Pyrimidines; Skin Neoplasms; Specific Pathogen-Free Organisms; Statistics, Nonparametric; Xenograft Model Antitumor Assays	2007

Other Studies

103 other study(ies) available for imatinib mesylate and Cancer of Skin

Article	Year
Facial subcutaneous dermatofibrosarcoma protuberans treated with imatinib and monitored with magnetic resonance: A therapeutic alternative for unresectable cases. Dermatologic therapy, 2022, Volume: 35, Issue:6 Topics: Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Skin Neoplasms	2022
Dermatofibrosarcoma protuberans with unusual presentation in vulva. Medicina, 2022, Volume: 82, Issue:3 Topics: Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Skin Neoplasms; Translocation, Genetic; Vulva	2022
Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate. Dermatologic therapy, 2022, Volume: 35, Issue:10 Topics: B7-H1 Antigen; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Ki-67 Antigen; Skin Neoplasms	2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants. Pigment cell & melanoma research, 2022, Volume: 35, Issue:6 Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Telomerase; Young Adult	2022
From Morphea to Dermatofibrosarcoma Protuberans. Acta dermatovenerologica Croatica : ADC, 2022, Volume: 30, Issue:2 Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult	2022
Oncological efficiency of wide local excision in dermatofibrosarcoma protuberans. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 77 Topics: Dermatofibrosarcoma; Follow-Up Studies; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms	2023
Review of dermatofibrosarcoma protuberans. Clinical and experimental dermatology, 2023, Mar-22, Volume: 48, Issue:4 Topics: Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-sis; Skin Neoplasms	2023
Construction of Imatinib Controlled Release Film-Forming System Based on Drug Ion-Pair and Oligomeric Ionic Liquids for the Long Local Therapy of Cutaneous Melanoma. AAPS PharmSciTech, 2023, Mar-25, Volume: 24, Issue:4 Topics: Administration, Cutaneous; Animals; Delayed-Action Preparations; Imatinib Mesylate; Ionic Liquids; Melanoma; Melanoma, Cutaneous Malignant; Mice; Oils; Skin; Skin Neoplasms; Spectroscopy, Fourier Transform Infrared	2023
Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance. JAMA network open, 2019, 08-02, Volume: 2, Issue:8 Topics: Adult; Delayed Diagnosis; Dermatofibrosarcoma; Diagnostic Errors; Female; Humans; Imatinib Mesylate; Interdisciplinary Placement; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Radiotherapy; Risk Assessment; Self-Help Groups; Skin Neoplasms; Social Media; Surveys and Questionnaires; Treatment Outcome	2019
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report. Medicine, 2019, Volume: 98, Issue:44 Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Treatment Outcome	2019
Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature. Journal of cutaneous pathology, 2020, Volume: 47, Issue:4 Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Sunitinib	2020
Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report. Journal of medical case reports, 2019, Dec-19, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Skin Neoplasms; Treatment Outcome	2019
Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Lymphomatoid Papulosis; Male; Middle Aged; Protein Kinase Inhibitors; Skin Neoplasms; Treatment Outcome	2020
Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease-Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS). Journal of surgical oncology, 2020, Volume: 122, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Oncogene Proteins, Fusion; Prognosis; Progression-Free Survival; Registries; Retrospective Studies; Skin Neoplasms; Young Adult	2020
Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle. Pharmaceutical research, 2020, May-31, Volume: 37, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cell Line, Tumor; Drug Liberation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-gamma; Liposomes; Melanoma, Experimental; Mice; Nanoparticles; RNA, Small Interfering; Skin Neoplasms; T-Lymphocytes, Cytotoxic	2020
Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report. Ceskoslovenska patologie, 2020,Spring, Volume: 56, Issue:2 Topics: Dermatofibrosarcoma; Fibrosarcoma; Humans; Imatinib Mesylate; Male; Skin Neoplasms; Translocation, Genetic	2020
Neoadjuvant imatinib as treatment preceding surgery for vulvar dermatofibrosarcoma protuberans. Dermatologic therapy, 2021, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Preoperative Care; Skin Neoplasms	2021
The various treatment modalities of dermatofibrosarcoma protuberans. Dermatology online journal, 2021, Jun-15, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Skin Neoplasms	2021
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease-Free Survival; Extremities; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Soft Tissue Neoplasms; Torso; Treatment Outcome; Young Adult	2017
Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. Acta dermato-venereologica, 2017, Jul-06, Volume: 97, Issue:7 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lymphomatoid Papulosis; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Skin Neoplasms; Treatment Outcome	2017
Breast and pleuropulmonary metastasis of multirecurrent scalp dermatofibrosarcoma protuberans: a case report. Journal of medical case reports, 2017, Apr-08, Volume: 11, Issue:1 Topics: Adult; Alopecia; Antigens, CD34; Antineoplastic Agents; Biopsy; Breast Neoplasms; Cough; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Pleural Neoplasms; Prognosis; Scalp; Skin Neoplasms; Treatment Outcome	2017
Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma research, 2017, Volume: 27, Issue:4 Topics: Female; Humans; Imatinib Mesylate; Ipilimumab; Melanoma; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2017
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:10 Topics: beta Catenin; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Melanoma; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin Neoplasms; Tumor Cells, Cultured	2017
[Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma]. Annales de pathologie, 2018, Volume: 38, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Combined Modality Therapy; Contraindications, Procedure; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Paraplegia; Radiotherapy, Adjuvant; Sacrococcygeal Region; Skin Neoplasms; Skin Ulcer; Soft Tissue Neoplasms	2018
[Management for locally advanced dermatofibrosarcoma protuberans in Togo]. Bulletin du cancer, 2018, Volume: 105, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Skin Neoplasms; Togo; Young Adult	2018
Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management. Anti-cancer drugs, 2018, Volume: 29, Issue:9 Topics: Adult; Antineoplastic Agents; Dermatofibrosarcoma; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Hypersensitivity Syndrome; Humans; Imatinib Mesylate; Male; Prednisone; Skin Neoplasms	2018
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. The Journal of investigative dermatology, 2019, Volume: 139, Issue:3 Topics: Antineoplastic Agents; Cancer Care Facilities; Cohort Studies; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Melanoma; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Skin Neoplasms; Survival Analysis; Texas; Treatment Outcome	2019
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World journal of surgical oncology, 2013, Mar-08, Volume: 11 Topics: Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Treatment Outcome	2013
Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase. BMJ case reports, 2013, Apr-15, Volume: 2013 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sarcoma, Myeloid; Skin Neoplasms	2013
Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines. Journal of plastic surgery and hand surgery, 2014, Volume: 48, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Denmark; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Piperazines; Plastic Surgery Procedures; Practice Guidelines as Topic; Prognosis; Pyrimidines; Retrospective Studies; Skin Neoplasms; Skin Transplantation; Young Adult	2014
Another option in our KIT of effective therapies for advanced melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Benzamides; Female; Gene Amplification; Humans; Imatinib Mesylate; Male; Melanoma; Mucous Membrane; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight	2013
Clinical remission of Merkel cell carcinoma after treatment with imatinib. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:4 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy, Needle; Carcinoma, Merkel Cell; Cheek; Fatal Outcome; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Skin Neoplasms; Subcutaneous Tissue; Treatment Outcome	2013
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. The Journal of investigative dermatology, 2014, Volume: 134, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Melanoma; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin Neoplasms	2014
Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. Oncology reports, 2014, Volume: 31, Issue:5 Topics: Animals; B-Lymphocytes; Benzamides; DNA-Binding Proteins; Drug Therapy, Combination; Female; Imatinib Mesylate; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Pyrimidines; Skin Neoplasms; T-Lymphocytes; Tumor Necrosis Factor Receptor Superfamily, Member 7	2014
Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma research, 2014, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biopsy; DNA Mutational Analysis; Exons; Fatal Outcome; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mucous Membrane; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stem Cell Factor	2014
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma. JAMA dermatology, 2014, Volume: 150, Issue:12 Topics: Aged, 80 and over; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Fatal Outcome; Female; Fibroblasts; Humans; Imatinib Mesylate; Lung Neoplasms; Melanoma; Mutation, Missense; Phosphorylation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Skin Neoplasms; Spinal Neoplasms; Thiazoles	2014
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature communications, 2014, Dec-15, Volume: 5 Topics: Aminopyridines; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Indoles; Melanoma; Mice; Microphthalmia-Associated Transcription Factor; Oximes; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidines; Pyrimidinones; Receptor Protein-Tyrosine Kinases; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays	2014
Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate. The Journal of dermatology, 2015, Volume: 42, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Skin Neoplasms	2015
Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report. Journal of medical case reports, 2015, Apr-29, Volume: 9 Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Combined Modality Therapy; Dermatofibrosarcoma; Eye Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Male; Middle Aged; Oncogene Proteins, Fusion; Orbit; Skin Neoplasms	2015
Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients. Medicine, 2015, Volume: 94, Issue:17 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; China; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2015
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Feb-15, Volume: 22, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2016
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget, 2016, Jul-19, Volume: 7, Issue:29 Topics: Animals; Cell Movement; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Xenograft Model Antitumor Assays	2016
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study. Cutis, 2016, Volume: 97, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms	2016
Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:17 Topics: Abdomen; Antineoplastic Agents; Dermatofibrosarcoma; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Skin Neoplasms	2016
Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. The Journal of investigative dermatology, 2017, Volume: 137, Issue:2 Topics: Adaptive Immunity; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Dermatofibrosarcoma; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Lectins, C-Type; Myeloid Cells; Receptors, Cell Surface; Skin Neoplasms; T-Lymphocytes	2017
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer, 2017, 02-15, Volume: 123, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Skin Neoplasms	2017
New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors. Anticancer research, 2016, Volume: 36, Issue:11 Topics: Aged; Carcinoma, Squamous Cell; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Second Primary; Proto-Oncogene Mas; Skin Neoplasms	2016
Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy? The Journal of investigative dermatology, 2017, Volume: 137, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunotherapy; Piperazines; Pyrimidines; Skin Neoplasms	2017
Letter: clear margins after the use of imatinib mesylate prior to resection of extensive dermatofibrosarcoma protuberans. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2008, Volume: 34, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Skin Neoplasms	2008
Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. Journal of cutaneous pathology, 2008, Volume: 35, Issue:11 Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Collagen; Combined Modality Therapy; Dermatofibrosarcoma; Female; Humans; Hyalin; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms	2008
Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report. Oral and maxillofacial surgery, 2008, Volume: 12, Issue:4 Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms	2008
Primary large gastrointestinal stromal tumor of the liver: report of a case. Surgery today, 2009, Volume: 39, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Skin Neoplasms; Stomach Neoplasms	2009
Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Archives of dermatology, 2009, Volume: 145, Issue:7 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Pyrimidines; Retrospective Studies; Skin Neoplasms	2009
Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology, 2009, Volume: 54, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Collagen Type I; Collagen Type I, alpha 1 Chain; Dermatofibrosarcoma; DNA Primers; Female; Gene Fusion; Genes, sis; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Piperazines; Pyrimidines; Skin Neoplasms; Young Adult	2009
Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. Journal of neurosurgery, 2010, Volume: 112, Issue:5 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Collagen Type I; Collagen Type I, alpha 1 Chain; Dermatofibrosarcoma; Epidermal Growth Factor; Humans; Imatinib Mesylate; Male; Middle Aged; Neurosurgical Procedures; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Scalp; Skin Neoplasms; Treatment Outcome	2010
Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Nevus, Halo; Piperazines; Pyrimidines; Skin Neoplasms	2010
[Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans]. Orvosi hetilap, 2009, Oct-11, Volume: 150, Issue:41 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Skin Neoplasms	2009
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. The Journal of investigative dermatology, 2010, Volume: 130, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2010
Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas. The American journal of pathology, 2010, Volume: 176, Issue:2 Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Proliferation; Cells, Cultured; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Transfection; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factor A	2010
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib	2010
Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb. Clinical and experimental dermatology, 2011, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Thumb	2011
Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. Journal of the European Academy of Dermatology and Venereology : JEADV, 2011, Volume: 25, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Collagen Type I; Collagen Type I, alpha 1 Chain; Combined Modality Therapy; Dermatofibrosarcoma; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Retrospective Studies; Sarcoma; Skin Neoplasms; Treatment Outcome	2011
Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms	2010
Keratoacanthomas associated with imatinib mesylate. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Keratoacanthoma; Male; Melanoma; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2011
[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Edema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Skin Neoplasms; Survival Rate; Vomiting	2011
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer cell, 2011, Dec-13, Volume: 20, Issue:6 Topics: Animals; Antigens, Differentiation; Benzamides; beta Catenin; Cell Transformation, Neoplastic; Colorectal Neoplasms; Enzyme Activation; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Melanocytes; Melanoma, Experimental; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Piperazines; Protein Stability; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Skin Neoplasms; Splenic Neoplasms; Transcription, Genetic; Tumor Cells, Cultured	2011
KIT mutations in a series of melanomas and their impact on treatment with imatinib. Actas dermo-sifiliograficas, 2012, Volume: 103, Issue:9 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Melanoma; Middle Aged; Mutation; Piperazines; Pyrimidines; Skin Neoplasms; Treatment Outcome	2012
From chemotherapy to targeted treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Melanoma; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sulfonamides; Vemurafenib	2012
[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]. Bulletin du cancer, 2002, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Florida; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Skin Neoplasms	2002
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	2002
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Radionuclide Imaging; Skin Neoplasms; Spinal Cord Neoplasms	2002
Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International journal of cancer, 2002, Aug-20, Volume: 100, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Recurrence; Sarcoma; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2002
[New oncological treatment principle with imatinib]. Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stromal Cells; Treatment Outcome	2003
[Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans]. Nederlands tijdschrift voor geneeskunde, 2003, Oct-18, Volume: 147, Issue:42 Topics: Adult; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms; Treatment Outcome	2003
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Nov-15, Volume: 21, Issue:22 Topics: Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Chromosome Aberrations; Cytogenetic Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms	2003
EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood, 2003, Dec-01, Volume: 102, Issue:12 Topics: Aged; B-Lymphocytes; Benzamides; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoproliferative Disorders; Neoplasms, Second Primary; Piperazines; Pyrimidines; Skin Neoplasms	2003
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. The Journal of investigative dermatology, 2004, Volume: 122, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Tumor; Humans; Imatinib Mesylate; Male; Melanoma; Mice; Mice, Nude; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays	2004
c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Investigative ophthalmology & visual science, 2004, Volume: 45, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Blotting, Western; Cell Division; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Melanoma; Middle Aged; Paraffin Embedding; Phosphorylation; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Messenger; Skin Neoplasms; Tumor Cells, Cultured; Tyrosine; Uveal Neoplasms	2004
Imatinib mesylate in cutaneous melanoma. The Journal of investigative dermatology, 2004, Volume: 123, Issue:6 Topics: Animals; Antineoplastic Agents; Benzamides; Imatinib Mesylate; Melanoma; Mice; Mice, Inbred C57BL; Piperazines; Pyrimidines; Skin Neoplasms	2004
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. European journal of haematology, 2005, Volume: 74, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma; Drug Eruptions; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Pyrimidines; Skin Neoplasms; Vomiting; Weight Gain	2005
Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anti-cancer drugs, 2005, Volume: 16, Issue:4 Topics: Benzamides; Chromosome Aberrations; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Skin Neoplasms	2005
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. British journal of cancer, 2005, May-23, Volume: 92, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Fanconi Anemia; Humans; Imatinib Mesylate; Melanoma; Mice; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Ewing; Skin Neoplasms; Telomerase; Tumor Cells, Cultured	2005
Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy. Journal of cutaneous pathology, 2006, Volume: 33, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Breast Neoplasms; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization; Lung Neoplasms; Mastectomy; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Ring Chromosomes; Skin Neoplasms	2006
Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Benzamides; Cheek; Dermatofibrosarcoma; Facial Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms	2006
Effective treatment of a case of refractory mycosis fungoides with imatinib. British journal of haematology, 2006, Volume: 133, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Mycosis Fungoides; Piperazines; Pyrimidines; Skin Neoplasms	2006
Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. Clinical and laboratory haematology, 2006, Volume: 28, Issue:3 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Brain Neoplasms; Fatal Outcome; Female; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms	2006
Intracranial recurrence of the scalp dermatofibrosarcoma. Clinical neurology and neurosurgery, 2007, Volume: 109, Issue:2 Topics: Adult; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Sinuses; Dermatofibrosarcoma; Embolization, Therapeutic; Female; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Scalp; Skin Neoplasms; Skull Neoplasms	2007
Somatic activation of KIT in distinct subtypes of melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-10, Volume: 24, Issue:26 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Microarray Analysis; Middle Aged; Nucleic Acid Hybridization; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2006
The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Melanoma; Middle Aged; Ovarian Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Skin Neoplasms; Uveal Neoplasms	2006
Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006, Volume: 32, Issue:8 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Diagnostic Imaging; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Skin Neoplasms; Thorax	2006
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anti-cancer drugs, 2006, Volume: 17, Issue:10 Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Positron-Emission Tomography; Pyrimidines; Scalp; Skin Neoplasms; Tomography, X-Ray Computed	2006
[A case of recurrent GIST of the esophagus which completely responded to imatinib mesilate]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms	2007
[From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors]. Bulletin du cancer, 2007, Volume: 94, Issue:2 Topics: Adult; Age Factors; Antineoplastic Agents; Benzamides; Child; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Ring Chromosomes; Skin Neoplasms; Translocation, Genetic	2007
[Targeted therapy of dermatofibrosarcoma with imatinib]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2007, Volume: 5, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials, Phase II as Topic; Dermatofibrosarcoma; Disease-Free Survival; Drug Delivery Systems; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms	2007
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC nephrology, 2007, Mar-27, Volume: 8 Topics: Aged, 80 and over; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Kidney Failure, Chronic; Kidney Transplantation; Male; Neoplasm Staging; Piperazines; Pyrimidines; Retreatment; Risk Assessment; Sarcoma, Kaposi; Sirolimus; Skin Neoplasms; Treatment Outcome	2007
Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007, Volume: 33, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms	2007
[Imatinib . Sunitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8 Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate	2007
Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2007, Volume: 48, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biopsy; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms	2007
Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate. Journal of cutaneous pathology, 2008, Volume: 35, Issue:2 Topics: Antineoplastic Agents; Benzamides; Carcinoma, Merkel Cell; Humans; Imatinib Mesylate; Immunohistochemistry; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Skin Neoplasms	2008
Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. Acta dermato-venereologica, 2008, Volume: 88, Issue:2 Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms	2008
Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-01, Volume: 26, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Piperazines; Positron-Emission Tomography; Pyrimidines; Skin Neoplasms	2008
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer research, 1999, Aug-01, Volume: 59, Issue:15 Topics: 3T3 Cells; Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Transformation, Neoplastic; Cosmids; Dermatofibrosarcoma; Enzyme Inhibitors; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms	1999
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer research, 2001, Aug-01, Volume: 61, Issue:15 Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Child, Preschool; Dermatofibrosarcoma; Female; Fibrosarcoma; Giant Cell Tumors; Growth Inhibitors; Humans; Imatinib Mesylate; Infant; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays	2001